SCHEMBL29526647

SCHEMBL29526647

COc1ccc(C(N)=O)cc1Nc1ncc(C(N)=O)c(Nc2ccccc2Br)n1

nearest known ligand 0.65

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 14/20 0.65
▸ MAPK8 P45983 1/20 0.56
▸ MAPK9 P45984 1/20 0.56
▸ JAK2 O60674 1/20 0.54
▸ JAK1 P23458 1/20 0.54
▸ TYK2 P29597 1/20 0.54
▸ JAK3 P52333 1/20 0.54
▸ CSF1R P07333 1/20 0.53
▸ LRRK2 Q5S007 1/20 0.51
▸ INSR P06213 1/20 0.50
▸ IGF1R P08069 1/20 0.50
▸ ALK Q9UM73 1/20 0.50
▸ MAPK3 P27361 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26970158 1.00 MAP4K1 (0.65) MAP4K1MAPK8MAPK9JAK2JAK1
SCHEMBL29526496 0.80 MAP4K1 (0.73) MAP4K1ALK
SCHEMBL26970277 0.80 MAP4K1 (0.73) MAP4K1ALK
SCHEMBL26970238 0.79 MAP4K1 (0.61) MAP4K1MAPK8MAPK9JAK2JAK1
SCHEMBL30689974 0.79 MAP4K1 (0.61) MAP4K1MAPK8MAPK9JAK2JAK1
SCHEMBL29525808 0.79 MAP4K1 (1.00) MAP4K1
SCHEMBL26970190 0.79 MAP4K1 (1.00) MAP4K1
Hydrochloric Acid SCHEMBL29525946 0.79 MAP4K1 (0.98) MAP4K1
SCHEMBL30689932 0.79 MAP4K1 (0.84) MAP4K1
SCHEMBL26970197 0.79 MAP4K1 (0.84) MAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4240362-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 Merck Sharp & Dohme LLC (US) 2023-09-13 — — EP claimed
WO-2022098809-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 MERCK SHARP & DOHME CORP. (US) 2022-05-12 — — WO claimed
US-20230416225-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 MERCK SHARP & DOHME LLC (US) 2023-12-28 — — US disclosed
EP-4240362-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 Merck Sharp & Dohme LLC (US) 2023-09-13 — — EP disclosed
WO-2022098809-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 MERCK SHARP & DOHME CORP. (US) 2022-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416225-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 PDXK, PHKG1, PHKG2 MAP4K1 59/4885MAPK8 591/4885MAPK9 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback